RegeneRx Biopharmaceuticals (United States)

Recent papers from RegeneRx Biopharmaceuticals (United States)

1. Intraosseous bone marrow concentrate delays total hip arthroplasty in osteoarthritis: A fifteen year matched cohort study with dose–response analysisInternational Orthopaedics · 2026
2. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female PatientsMuscle & Nerve · 2026
3. Relationship Between Tobacco Product Use and Health-Related Quality of Life Among Individuals With COPD in Waves 1–5 (2013–2019) of the Population Assessment of Tobacco and Health StudyChronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2023
4. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based InhibitorsMolecular Cancer Therapeutics · 2023
5. A single post‐exposure oxime RS194B treatment rapidly reactivates acetylcholinesterase and reverses acute symptoms in macaques exposed to diethylphosphorothioate parathion and chlorpyrifos insecticidesJournal of Neurochemistry · 2023
6. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic propertiesmAbs · 2020
7. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetesDiabetes Obesity and Metabolism · 2019
8. Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavengerAnnals of the New York Academy of Sciences · 2016
9. Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profileThe Journal of Clinical Pharmacology · 2015
10. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patientsAnnals of the New York Academy of Sciences · 2012
11. Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double‐blind, clinical trialAnnals of the New York Academy of Sciences · 2012
12. Thymosin β4: a potential novel dry eye therapyAnnals of the New York Academy of Sciences · 2012
13. Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II TrialJournal of Clinical Oncology · 2011
14. A randomized, placebo‐controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteersAnnals of the New York Academy of Sciences · 2010
15. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin β4Annals of the New York Academy of Sciences · 2010
16. Thymosin β4: structure, function, and biological properties supporting current and future clinical applicationsAnnals of the New York Academy of Sciences · 2010
17. Development of Thymosin β4 for Treatment of Patients with Ischemic Heart DiseaseAnnals of the New York Academy of Sciences · 2007
18. Dual Effects of p38 MAPK on TNF-Dependent Bronchoconstriction and TNF-Independent Neutrophil Recruitment in Lipopolysaccharide-Induced Acute Respiratory Distress SyndromeThe Journal of Immunology · 2005